Lightning Round: Arcus Biosciences is speculative, it's too risky to fully bank on, says Jim Cramer

Key Concepts:

• Clear Cell Renal Cell Carcinoma
• Cancer Immunotherapy
• Clinical Trials
• Tumor Reduction
• Speculative Stock
• Cost Basis
• Nuclear Energy

Arcus Biosciences (ARCT): Cancer Immunotherapy and Clinical Trials

• The Situation: George from New York calls in to discuss Arcus Biosciences (ARCT), a company pioneering cancer immunotherapy treatments. His mother is battling clear cell renal cell carcinoma, a disease that hits close to home for the host.
• Arcus Biosciences' Pipeline: Arcus has multiple treatments in various clinical stages.
• Casetafan: The most prominent drug is casetafan, which is part of a combination treatment trial.
• Clinical Trial Results: The combination treatment trial is showing "extremely promising results," with "almost all patients" achieving tumor reduction.
• Financials and Risk: The host acknowledges that Arcus Biosciences has been "losing a lot of money."
• Recommendation: The host suggests that Arcus Biosciences can be a speculative stock in a diversified portfolio. He cautions against putting all investments into Arcus due to its risk profile.
• Quote: "There's room for one speculation in everybody's portfolio. Let this be your speculation. But if you do this, you have to promise me that the other stocks are not going to be speculative because it's too risky to just bank it all on Arcus."

UnitedHealthCare (UNH) and Healthcare Sector

• Caller's Question: Carl from Colorado calls in to discuss UnitedHealthCare (UNH).
• Past Shenanigans: The host acknowledges that UnitedHealthCare has had "shenanigans" in the past.
• CEO Quality: Despite past issues, the host believes that the company is currently run by a "very good CEO."
• Potential Comeback: The host suggests that UnitedHealthCare "could come back."

Uranium Energy Corp. (UEC) and Nuclear Energy

• Caller's Question: Mike from Pennsylvania calls in to ask about Uranium Energy Corp. (UEC).
• Nuclear Energy Endorsement: The host expresses a positive view on nuclear energy.
• Stock Performance: The host acknowledges that UEC's stock price has been increasing "in a straight line."
• Profit Focus: The host emphasizes his goal of making money for viewers.
• Quote: "Do I care that it's up in a straight line? Not anymore. No. Because, like, when I bought that, I told you about that. Alcohol doubled. I want money to be made. That's what I'm here for."

Conclusion:

The segment covers three different stocks across different sectors: Arcus Biosciences (biotech/cancer immunotherapy), UnitedHealthCare (healthcare), and Uranium Energy Corp. (nuclear energy). The host provides specific insights and recommendations for each, emphasizing the importance of diversification and risk management, particularly when considering speculative stocks like Arcus Biosciences. He also highlights the potential for turnaround stories, as seen with UnitedHealthCare, and the importance of profit generation, as demonstrated by his positive stance on Uranium Energy Corp. despite its rapid price increase.